Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Platelet response
研究概览
简要总结
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.
详细描述
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult ITP patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.
The subjects include ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.
Fifty-two eligible subjects will be enrolled in this study. The dose will be adjusted according to the platelet count during the period from week 1 to week 12.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patients have provided written informed consent prior to enrollment.
- •Men and women greater than or equal to 18 years of age.
- •Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.
- •Platelet count<30 ×10^9/L at screening.
- •Patients who have previously failed to receive Eltrombopag or Herombopag [poor efficacy (Eltrombopag 75 mg/d or Herombopag 7.5 mg/D, at least 4 weeks), or the efficacy cannot be maintained], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment.
- •Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment.
- •Effective contraceptive measures will be taken during the clinical trial.
排除标准
- •Patients with active thyroid disease requiring treatment.
- •Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening.
- •Those who had received rituximab within 3 months.
- •Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks).
- •Subjects known to be allergic to Avatrombopag or any of its excipients.
- •Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months.
- •Patients with lupus encephalopathy or lupus nephritis.
- •Patients with cataract.
- •Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening.
- •Existing hepatitis B virus, hepatitis C virus replication or HIV infection.
- •Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase > 3×ULN).
- •Patients with severe cardiac or pulmonary dysfunction.
- •Severe renal damage (creatinine clearance < 30 ml/min).
- •There are surgical planners during the study.
- •History of psychiatric disorder.
- •Pregnant or lactating women or those planning to be pregnant during the trial.
- •Patients with a history of drug/alcohol abuse (within 2 years before the study).
- •Patients that had participated in other experimental researches within one month before enrollment.
- •Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.
研究组 & 干预措施
Treatment group
Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag
干预措施: Avatrombopag (Drug)
结局指标
主要结局
Platelet response
时间窗: From the start of study treatment (Day 1) up to the end of week 12.
Percentage of participants achieving a platelet count \>=30×10\^9/L and at least doubling of the baseline count within 12 weeks of treatment.
次要结局
- Duration of platelet response(From the start of study treatment (Day 1) up to the end of week 12.)
- Time to platelet response(From the start of study treatment (Day 1) up to the end of week 12.)
- Functional assessment of chronic illness therapy-fatigue(From the start of study treatment (Day 1) up to the end of week 12.)
- Proportion of patients receiving remedial treatment.(From the start of study treatment (Day 1) up to the end of week 12.)
- Changes of disease activity index in patients with systemic lupus erythematosus(From the start of study treatment (Day 1) up to the end of week 12.)
- Improvement in immune indexes(From the start of study treatment (Day 1) up to the end of week 12.)
- Platelet response(From the start of study treatment (Day 1) up to the end of week 12.)
- Discontinuation rate of glucocorticoids(From the start of study treatment (Day 1) up to the end of week 12.)
- Bleeding score(From the start of study treatment (Day 1) up to the end of week 12.)
- The improvement of symptoms(From the start of study treatment (Day 1) up to the end of week 12.)
- ITP-Patient Assessment Questionnaire(From the start of study treatment (Day 1) up to the end of week 12.)